Group 1 - The company, 泰德医药 (Tide Pharmaceutical), plans to globally offer 16.8 million H-shares, with 1.68 million shares available in Hong Kong and 15.12 million shares for international offering [1] - The subscription period for the shares is set from June 20 to June 25, 2025, with the expected pricing date on June 26, 2025, and trading on the Hong Kong Stock Exchange anticipated to start on June 30, 2025 [1] - The proposed price range for the shares is between HKD 28.40 and HKD 30.60, with a trading unit of 100 shares [1] Group 2 - According to Frost & Sullivan, the company is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023 [2] - The company provides a full cycle of services from early discovery, preclinical research, clinical development to commercial production, primarily focusing on API rather than finished drugs [2] - The company has established stable customer relationships in over 50 countries, including major markets such as China, the USA, Japan, Europe, South Korea, and Australia [2] Group 3 - The company has signed cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of 2.6608 million shares at a hypothetical price of HKD 29.50, amounting to approximately USD 10 million (around HKD 78.49 million) [3] - The estimated net proceeds from the global offering are approximately HKD 411.2 million, assuming a share price of HKD 29.50 [3] - The intended use of the net proceeds includes approximately 76.4% for expanding service capacity and production facilities in the USA and China, 4.1% for expanding capacity in China, 9.5% for establishing sales and after-sales service networks in more regions, and 10.0% for working capital and other general corporate purposes [3]

Market Overview - On June 19, the Hang Seng Index fell by 1.99%, closing at 23,237.74 points, with a total net inflow of HKD 1.427 billion through the southbound trading channel [1][3] - The total trading volume for the southbound trading was HKD 118.861 billion, with a net buy of HKD 1.427 billion [1] Southbound Trading Details - The Shanghai Stock Exchange's southbound trading had a total transaction amount of HKD 77.453 billion, with a net buy of HKD 1.065 billion; the Shenzhen Stock Exchange's southbound trading had a total transaction amount of HKD 41.408 billion, with a net buy of HKD 0.363 billion [1] - The top active stocks in the Shanghai southbound trading included Meituan-W with a transaction amount of HKD 34.09 billion, followed by Pop Mart and China Construction Bank with transaction amounts of HKD 33.62 billion and HKD 30.48 billion, respectively [1] Stock Performance - In terms of net buy amounts, Xiaomi Group-W led with a net buy of HKD 0.385 billion, despite its closing price dropping by 1.39% [1] - Tencent Holdings had the highest net sell amount at HKD 0.723 billion, with a closing price decrease of 1.97% [1] - In the Shenzhen southbound trading, Pop Mart topped the transaction amount with HKD 21.32 billion, followed by Tencent Holdings and Meituan-W with HKD 20.99 billion and HKD 19.46 billion, respectively [2] Active Stocks Summary - The top active stocks and their respective transaction amounts and net buy/sell figures are as follows: - Meituan-W: Transaction amount HKD 340.91 million, net sell HKD 43.11 million, daily change -3.75% [2] - Pop Mart: Transaction amount HKD 336.18 million, net sell HKD 29.07 million, daily change -5.33% [2] - China Construction Bank: Transaction amount HKD 304.80 million, net buy HKD 37.00 million, daily change -2.22% [2] - Tencent Holdings: Transaction amount HKD 287.58 million, net sell HKD 72.31 million, daily change -1.97% [2]

Market Overview - On June 19, the Hang Seng Index fell by 1.99%, with southbound trading totaling HKD 118.86 billion, comprising HKD 60.14 billion in buying and HKD 58.72 billion in selling, resulting in a net buying amount of HKD 1.43 billion [1][2] Southbound Trading Details - Southbound trading through the Stock Connect (Shenzhen) recorded a total transaction amount of HKD 41.41 billion, with buying at HKD 20.88 billion and selling at HKD 20.52 billion, leading to a net buying of HKD 0.36 billion [1] - Southbound trading through the Stock Connect (Shanghai) had a total transaction amount of HKD 77.45 billion, with buying at HKD 39.26 billion and selling at HKD 38.19 billion, resulting in a net buying of HKD 1.07 billion [1] Active Stocks - The most actively traded stock by southbound funds was Pop Mart, with a total transaction amount of HKD 54.94 billion, followed by Meituan-W at HKD 53.55 billion and Tencent Holdings at HKD 49.75 billion [1][2] - Among the net buying stocks, Xiaomi Group-W led with a net buying amount of HKD 4.96 billion, despite a closing price drop of 1.39% [1][2] - China Construction Bank had a net buying of HKD 3.70 billion, while ZhongAn Online saw a net buying of HKD 2.78 billion [1] Net Selling Stocks - Tencent Holdings experienced the highest net selling amount of HKD 13.09 billion, with a closing price decline of 1.97% [1][2] - Pop Mart and Alibaba-W faced net selling amounts of HKD 8.35 billion and HKD 2.06 billion, respectively [1][2] Continuous Net Buying - China Construction Bank was noted for having continuous net buying for 7 days, with a total net buying amount of HKD 4.32 billion during this period [2]

Core Insights - On June 19, 2025, Meituan-W (03690), Pop Mart (09992), and China Construction Bank (00939) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 3.409 billion, 3.362 billion, and 3.048 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Pop Mart (09992), Tencent Holdings (00700), and Meituan-W (03690) led the trading volume, with amounts of 2.132 billion, 2.099 billion, and 1.946 billion respectively [1] Southbound Stock Connect - Top Active Companies - Meituan-W (03690) had a trading amount of 3.409 billion with a net buy of -431 million [2] - Pop Mart (09992) recorded a trading amount of 3.362 billion with a net buy of -291 million [2] - China Construction Bank (00939) achieved a trading amount of 3.048 billion with a net buy of +370 million [2] - Tencent Holdings (00700) had a trading amount of 2.876 billion with a net buy of -723 million [2] - Alibaba-W (09988) had a trading amount of 2.112 billion with a net buy of +51 million [2] Shenzhen-Hong Kong Stock Connect - Top Active Companies - Pop Mart (09992) led with a trading amount of 2.132 billion and a net buy of -544 million [2] - Tencent Holdings (00700) followed with a trading amount of 2.099 billion and a net buy of -586 million [2] - Meituan-W (03690) had a trading amount of 1.946 billion with a net buy of +313 million [2] - Alibaba-W (09988) recorded a trading amount of 1.348 billion with a net buy of -257 million [2] - Xiamen International Bank (01801) had a trading amount of 1.109 billion with a net buy of +35 million [2]

15 June 2025 | 1:53PM HKT Potential opportunities on other technology platforms: Referring to technology platform-based collaborations between China pharma / biotech and MNCs (see summary in Exhibit 1), the upfront payment of US$110mn for the announced AZ/CSPC collaboration is consistent with the historical range of US$10mn to below US$200mn, while the total deal size of US$5.3bn was the highest since 2023. With the current collaboration announced to date, we see growing recognition from MNCs for CSPC's tec ...

Group 1 - The Hong Kong stock market for innovative drug concept stocks continues to decline, with notable drops in several companies [1] - Zai Lab (09688.HK) and Innovent Biologics (02096.HK) both fell over 7% [1] - Other companies such as Luye Pharma (02186.HK) and Genscript Biotech (01952.HK) experienced declines of over 6%, while CSPC Pharmaceutical Group (01093.HK) dropped by 5.9% [1]

恒指跌1%，恒生科技指数跌0.9%，创新药股走低，石药集团(01093.HK)跌3.6%。 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HK$10.59, representing a potential upside of 20% from the current price of HK$8.84 [1][8][18]. Core Insights - The company has faced revenue declines in its core pharmaceutical business but has offset some of this through strong licensing income, demonstrating its ability to commercialize its pipeline effectively [6][15]. - The report highlights a strategic partnership with AstraZeneca, which includes an upfront payment of US$110 million, indicating strong collaboration in innovative drug development [6][15]. - Adjustments to earnings per share (EPS) forecasts reflect a cautious outlook on the growth of the company's core generic drug business, with 2025 and 2026 EPS estimates reduced by 14% [2][11]. Financial Performance - The company reported a revenue of RMB 70.15 billion in Q1 2025, a year-on-year decline of 21.9%, while net profit was RMB 14.95 billion, down 8.3% [6][10]. - The revenue forecast for 2025 has been adjusted down to RMB 28.306 billion, a decrease of 12% from previous estimates, with a further decline expected in 2026 [12][15]. - The report anticipates a gross margin of 70% for 2025, slightly lower than previous forecasts, reflecting ongoing challenges in the market [11][12]. Research and Development - The company continues to invest in R&D, with expenditures reaching RMB 13 billion in Q1 2025, representing an 11.4% increase year-on-year [7][11]. - The R&D intensity remains high at 23.7% of revenue, indicating a strong commitment to innovation [7][11]. - The company has nearly 90 products in various stages of clinical development, with several already submitted for registration, enhancing future approval efficiency [7][11]. Valuation - The report employs a two-stage DCF model for valuation, adjusting the WACC to 8.5% and increasing the perpetual growth rate to 4% [8][17]. - The target price of HK$10.59 is based on the DCF analysis, suggesting that the current valuation does not fully reflect the company's growth potential in innovative drugs and licensing income [8][17]. - The company's projected P/E ratio for 2025 is 21, slightly above the industry average of 20, indicating a potential undervaluation relative to its peers [8][17].

港股创新药板块午后持续下挫，先声药业跌近12%，石药集团跌超6%。 ...

Core Insights - The innovative drug sector in China has experienced a significant surge since June, with both A-share and Hong Kong markets showing strong performance in related stocks. This "medication boom" is driven by Chinese innovative pharmaceutical companies achieving strategic breakthroughs in global expansion through licensing deals [1][2]. Group 1: BD Transactions - The BD (Business Development) transactions have exploded since May, with notable deals such as the $60.5 billion licensing agreement between 3SBio and Pfizer, which set a record for the highest upfront payment for a Chinese innovative drug license-out [2]. - Other companies like CSPC Pharmaceutical Group and Innovent Biologics have also announced high-value BD transactions, with upfront payments ranging from $15 million to $180 million [2]. - The trend indicates that licensing income is becoming a core driver of profit growth for innovative drug companies, with significant upfront payments translating into immediate profits [5][6]. Group 2: Global Competitive Advantage - Multinational pharmaceutical companies are increasingly favoring Chinese innovative drugs due to technological breakthroughs, clinical advantages, cost efficiency, and external demand [3]. - China demonstrates global competitiveness in cutting-edge fields such as dual antibodies and ADCs, with recognized quality and shorter R&D cycles, making it attractive for foreign firms seeking high returns [3]. - The significant gap in the market due to expiring patents for blockbuster drugs is driving strong demand for Chinese innovative assets [3]. Group 3: Market Performance - The A-share pharmaceutical index has risen by 11.02% year-to-date, with individual stocks like Hebei Changshan Biochemical and Nanjing Haisco Pharmaceutical seeing price increases of over 200% in the past two months [5]. - Several actively managed pharmaceutical funds have reported growth rates exceeding 60% this year, indicating strong market interest and investment in the sector [5]. Group 4: Policy Support - The Chinese government continues to implement supportive policies for innovative drug development, including expedited review processes for clinical trial applications [7]. - The State Council has emphasized the need to enhance the innovation capabilities of pharmaceutical companies to better meet diverse healthcare needs [8]. - Systematic policy support covering the entire lifecycle of drug development is expected to create a sustainable innovation ecosystem, providing long-term institutional guarantees for industry growth [8].